Stryker (NYSE:SYK) turned in one of its stronger quarters in recent memory on July 30, with sales climbing 9.4% to $6.6 billion and reported EPS jumping 44.1% to $3.30. The numbers arrive as the company works its way back from a cyber incident that had rattled its business, and CEO Kevin Lobo pointed to that recovery as proof of the company’s resilience. But a closer look at how those earnings were adjusted tells a more complicated story about what is really driving the bottom line.
Bull Case: Growth That Touched Every Corner Of The Business
Both of Stryker’s segments grew at nearly the same pace in the quarter, which is notable given how different their products are. MedSurg and Neurotechnology sales rose 9.7% to $3.6 billion, with organic growth of 9.2%, almost all of it from more units sold rather than higher prices. Orthopaedics sales climbed 9.1% to $3.0 billion, with organic growth of 8.6%, also driven almost entirely by volume. That pattern matters: when growth comes from selling more products rather than raising prices or buying other companies, it points to genuine demand.
Acquisitions and divestitures added essentially nothing to the total, so the 9.0% organic growth figure and the 9.4% reported figure landed nearly identical. Profitability moved the same way. Adjusted operating income margin expanded 170 basis points to 27.4%, and adjusted gross profit margin came in at 66.0%. Stryker also narrowed its full-year guidance, now expecting organic net sales growth of 8.3% to 9.3% and adjusted EPS of $14.95 to $15.10.
Bear Case: How Much Of That Growth Is Really Growth
The gap between Stryker’s reported and adjusted results is where the story gets murkier. Reported EPS jumped 44.1% to $3.30, more than double the 17.9% increase in adjusted earnings per share to $3.69. That gap exists because Stryker excluded a long list of items to get to its adjusted numbers, including charges tied to acquisitions and integration, amortization of purchased intangible assets, structural optimization, goodwill and other impairments, costs to comply with medical device regulations, recall-related matters, and regulatory and legal matters.
Each of those categories represents a real cost sitting somewhere in Stryker’s business, even after it gets stripped out of the adjusted figures investors tend to focus on. The reported operating income margin of 25.2% also sat more than two full points below the adjusted margin of 27.4%, another sign of how much is being excluded. And the quarter’s strength is measured against a stretch when Stryker was still working through the aftermath of a cyber incident, which makes the comparison an easier one to clear.
What The Market Is Pricing In
Hedge fund ownership of Stryker rose from 67 funds to 81 in the most recent quarter, pointing to growing institutional conviction. Short interest sits at just 1.91% of the float, a level that suggests little organized skepticism toward the stock. As of August 11, Stryker trades at a forward P/E of 22.99, a multiple that assumes the growth investors just saw keeps going rather than fades.
The Real Test Is Still Ahead
Stryker’s second quarter shows a company genuinely rebuilding momentum, with volume-driven growth across both segments and a full year outlook that got more precise rather than more cautious. But the wide gap between reported and adjusted earnings, and the long list of items excluded to get there, means the headline numbers only tell part of the story. For the growth to hold, Stryker needs the volume gains in MedSurg and Orthopaedics to keep compounding without leaning on price.
While we acknowledge the risk and potential of SYK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SYK and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center